PER 13.0% 13.0¢ percheron therapeutics limited

Sarepta gene therapy study missed key target in Duchennes, page-112

  1. 3,256 Posts.
    lightbulb Created with Sketch. 282
    Check out this website it may give you more understanding:
    Parent Project Muscular Dystrophy (PPMD) | Fighting to End Duchenne

 
watchlist Created with Sketch. Add PER (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.